

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

## EQA round: BIL2/18 - Bilirubin Neonatal

Dead line: 24.08.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Traceability														
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>							
<b>(215) Bilirubin total</b>					142						0				142	142	100%				
--- Samples and groups ---	[µmol/L]																				
<b>Sample A</b>		145	7,8	5,4	142						0	CRV	144	3,3	20%	115	173	142	142	100%	
(1) Abbott		146	4,5	3,1	13	0												13			
(12) Beckman Coulter		141	3,1	2,2	5	0												5			
(58) Beckman Coulter (Olympus)		143	4,0	2,8	30	0												30			
(60) Roche		140	4,8	3,5	42	0												42			
(149) Siemens (Dade)		151	3,7	2,5	15	0												15			
(179) Siemens (Bayer)		158	6,1	3,9	18	0												18			
Other					19	0												19			
-----																					
<b>Sample B</b>		325	21	6,6	142						0	CRV	1x 40, 3x 46, 3x 49, 1x 61, 1x 70, 1x 77, 3x 158, 1x 166, 2x 178, 3x 998	317	6,7	20%	253	381	142	142	100%
(1) Abbott		332	12	3,5	13	0												13			
(12) Beckman Coulter		321	11	3,5	5	0												5			
(58) Beckman Coulter (Olympus)		313	11	3,6	30	0												30			
(60) Roche		311	9,7	3,1	42	0												42			
(149) Siemens (Dade)		341	9,8	2,9	15	0												15			
(179) Siemens (Bayer)		359	13	3,7	18	0												18			
Other					19	0												19			

st\_kn\_np

End of report

Printed: 30.08.2018